The European Study of Screening for Prostate Cancer revealed that screening significantly reduces death from prostate cancer, and that a man who undergoes PSA testing will have his risk of dying from prostate cancer reduced by 29% [17, 18], and [19]. Here, KLK3 is linked to prostate cancer.